Achaogen, Inc. operates as a clinical-stage biopharmaceutical company, which engaegs in discovering, developing, and commercializing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections. It also offers plazomicin for the treatment of serious bacterial infections. The company was by Ian R. Friedland and Nathaniel E. David founded in June 2002 and is headquartered in South San Francisco, CA.
